All Acute myeloid leukaemia (AML) articles
-
News
Amgen acquires UK cancer biotech Dark Blue Therapeutics for $840m
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.
-
NewsTargeted therapy for hard-to-treat leukaemia subtype approved in EU
A FLT3 inhibitor that has been shown to significantly improve FLT3-ITD positive acute myeloid leukaemia survival has been authorised in the EU.
-
NewsCHMP’s September 2023 meeting highlights
In its September 2023 meeting, the EMA’s human medicines committee (CHMP) recommended nine medicines for approval and the extension of therapeutic indications for 11 medicines.